Biopharmaceutical Venture Capital Trends: Coronavirus Disease (COVID-19) Company Impact Report

Biopharmaceutical Venture Capital Trends: Coronavirus Disease (COVID-19) Company Impact Report

  • April 2020 •
  • 32 pages •
  • Report ID: 5892813 •
  • Format: PDF
Biopharmaceutical Venture Capital Trends: Coronavirus Disease (COVID-19) Company Impact Report

Summary
This report examines the impact of the COVID-19 pandemic on venture capital deals for biopharmaceutical companies. This analysis is critical to understanding how the outbreak of COVID-19 impacted investments and how those VC deal trends may impact current and future venture capital investments.

Scope
This report is required reading for -
- Investors that want to understand how COVID-19 has impacted VC deals in the biopharmaceutical industry as well as identifying companies that may be due for a round of financing in upcoming months
- Companies that are due to raise venture capital in the near future and need to consider 2020 VC trends into their capital raising strategies.
- Large pharma companies with investment groups or BD teams looking for partnership opportunities where companies may be in need of financing with changing VC trends during the COVID-19 pandemic.

Reasons to Buy
- Monthly trends of VC deals by value and volume; including an analysis of monthly VC activity in China versus U.S. during the spread of the diease
- Analyzes how COVID-19 has shifted investment trends by deal value, round, and therapeutic area
- Assessment of investors activity level in biopharmaceutical VC deals prior to and during the COVID-19 pandemic
- Identify biopharmaceutical companies that may be looking for rounds of financing and how they may be impacted by the shifted trends in VC investment
Loading...

We are very sorry, but an error occurred.
Please contact support@reportbuyer.com if the problem remains.